STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo

Ji, Guoxin; Li, Jiyu

doi:10.1080/15384047.2019.1685290

Cited by 23 publications

(33 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, low expression of STEAP2 was detected in breast cancer previously [37], consistent with the findings in this study. And suppression of the STEAP2 level can promote cell proliferation and invasion by inducing EMT and activating the PI3K/AKT signaling pathway [37]. Additionally, the expression of STEAP2 also was evaluated to be a potential good predictor for patients with breast cancer.…”

Section: Discussionsupporting

confidence: 92%

“…Besides, STEAP2 was also highly expressed in colorectal cancer and drives the excessive proliferation of colon tumor cells [36]. Surprisingly, low expression of STEAP2 was detected in breast cancer previously [37], consistent with the findings in this study. And suppression of the STEAP2 level can promote cell proliferation and invasion by inducing EMT and activating the PI3K/AKT signaling pathway [37].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. To investigate the expression patterns and prognostic values of STEAP family members in the occurrence and development of breast cancer. Materials and Methods. The Human Protein Atlas was used to analyze the expression level of STEAPs in human normal tissues and malignant tumors. ONCOMINE datasets were analyzed for the comparison of the STEAPs levels between malignant cancers and corresponding normal tissues. Kaplan-Meier plotter was used to analyze the prognostic value of STEAPs in breast cancer patients. Results. STEAPs were widely distributed in human normal tissues with diverse levels. Normally, it is predicted that STEAP1 and STEAP2 were involved in the mineral absorption process, while STEAP3 participated in the TP53 signaling pathway and iron apoptosis. The results from ONCOMINE showed downregulation of STEAP1, STEAP2, and STEAP4 in breast cancers. Survival analysis revealed that breast cancer patients with high levels of STEAP1, STEAP2, and STEAP4 had a good prognosis, while those with low expression had high overall mortality. Conclusion. STEAP1, STEAP2, and STEAP4 are predicted to be the potential prognostic biomarkers for breast cancer patients, providing novel therapeutic strategies for them.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 91%

The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In our study, STEAP2 was significantly down-regulated in GBM tissues and inversely associated with survival. Moreover, STEAP2 down-regulation could promote cell proliferation and invasion by activating the PI3K/AKT/mTOR signalling pathway which is also an activated pathway involved in GBM tumorigenesis [40,42]. This indicates a new research objective for future studies exploring the role of STEAP2 in GBM growth, progression and prognosis.…”

Section: Discussionmentioning

confidence: 98%

“…STEAP2 is located on chromosome 7q21.13 close to STEAP1 and STEAP4 genes and plays a role in iron and copper reduction [38]. Its role has been confirmed in prostate and breast cancer in previous studies [39,40] but has not been studied in GBM. STEAP2 expression has been found to be significantly increased in prostate cancer, and its knockdown reduced the invasive potential of prostate cancer cells [41].…”

Section: Discussionmentioning

confidence: 99%

“…STEAP2 expression has been found to be significantly increased in prostate cancer, and its knockdown reduced the invasive potential of prostate cancer cells [ 41 ]. On the other hand, it is down-regulated in breast cancer tissues, and its low expression was associated with malignant phenotype and poor prognosis [ 40 ]. In our study, STEAP2 was significantly down-regulated in GBM tissues and inversely associated with survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma

Prasad

Tian

2020

Mol Neurobiol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most aggressive and common primary central nervous system tumour. Despite extensive therapy, GBM patients usually have poor prognosis with a median survival of 12–15 months. Novel molecular biomarkers that can improve survival prediction and help with treatment strategies are still urgently required. Here we aimed to robustly identify a gene signature panel for improved survival prediction in primary GBM patients. We identified 2166 differentially expressed genes (DEGs) using meta-analysis of microarray datasets comprising of 955 samples (biggest primary GBM cohort for such studies as per our knowledge) and 3368 DEGs from RNA-seq dataset with 165 samples. Based on the 1443 common DEGs, using univariate Cox and least absolute shrinkage and selection operator (LASSO) with multivariate Cox regression, we identified a survival associated 4-gene signature panel including IGFBP2, PTPRN, STEAP2 and SLC39A10 and thereafter established a risk score model that performed well in survival prediction. High-risk group patients had significantly poorer survival as compared with those in the low-risk group (AUC = 0.766 for 1-year prediction). Multivariate analysis demonstrated that predictive value of the 4-gene signature panel was independent of other clinical and pathological features and hence is a potential prognostic biomarker. More importantly, we validated this signature in three independent GBM cohorts to test its generality. In conclusion, our integrated analysis using meta-analysis approach maximizes the use of the available gene expression data and robustly identified a 4-gene panel for predicting survival in primary GBM.

show abstract

Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer

Li,

Jiang

2024

J Appl Genetics

View full text Add to dashboard Cite

Globally, breast cancer (BC) is the leading cause of female death and morbidity. Homologous recombination repair (HRR) is critical in BC. However, the prognostic role and immunotherapy response of HRR in BC remains to be clarified. Firstly, we identified HRR types in BC samples from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) dataset (GSE42568) based on 65 HRR genes (HRRGs). A differentially expressed gene (DEG) list for different HRR types was generated. Then, the influences of gene sets composed of these DEGs on biological pathways and BC prognosis were explored. Next, we identified gene clusters based on gene sets composed of DEGs. Genes associated with prognosis for DEGs were identified using univariate Cox regression. Finally, the HRR score was constructed based on genes associated with prognosis. We analyzed how HRR score correlates with tumor mutation burden (TMB), immune cell infiltration (ICI), and immunotherapy response. Three HRR clusters were discovered. HRR subtype A demonstrated decreased infiltration and a high number of immunosuppressive cells with a poor prognosis. DEGs among various HRR types were predominantly enriched in cell cycle and genomic stability-related pathways. The prognostic model based on sixteen DEGs accurately predicted BC prognosis. The HRRGs were differentially expressed in three DEG clusters. TMB, ICI, and immunotherapy responses differed significantly between the high and low HRR groups (HSG, LSG). The HSG was distinguished by a high degree of ICI and low TMB. LSG had a better response to anti-PD-1 or anti-PD-1 and anti-CTLA4 combination therapy. This work revealed that HRR patterns would contribute to predicting prognosis and immunotherapy response in BC, which may benefit patients.

show abstract

STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo

Cited by 23 publications

References 33 publications

The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer

The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer

Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma

Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer

Contact Info

Product

Resources

About